Regeneron Pharmaceuticals Inc
REGN
NASDAQ. Currency in USD
721.10 -2.07 ( -0.29% )
Market Cap.
78.53B
Beta (5Y monthly)
0.21
Price/Earnings
13.64
EPS (TTM)
56.12
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
459,144
1y Target Est.
802.25
Day's Range
52 Week's Range
Historical Summary
Performance
1 Month
-2.12%
YTD
14.18%
1Y
16.44%
2Y
44.54%
20.24% ann.
3Y
93.56%
24.62% ann.
5Y
86.95%
13.33% ann.
10Y
310.53%
15.17% ann.
EPS growth
1Y
-7.38%
2Y
89.47%
37.68% ann.
3Y
134.03%
32.76% ann.
5Y
297.45%
31.79% ann.
10Y
2,650.98%
39.31% ann.
20Y
2,201.87%
16.98% ann.
Share Buybacks
3 Months
1.05%
6 Months
0.27%
1Y
0.97%
2Y
0.97%
3Y
1.23%
5Y
3.61%
10Y
2.62%
20Y
-157.80%
About Regeneron Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Website
https://www.regeneron.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
105.72M
Employees
10915
Address
777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707
Latest news

Sanofi (SNY) Dupixent Gets CHMP Nod to Eosinophilic Esophagitis
The CHMP recommends approval of Sanofi (SNY) and partner Regeneron's Dupixent for the treatment of...
By Zacks Investment Research - 6 weeks ago

Ultragenyx's (RARE) Portfolio of Marketed Drugs Aids Growth
Ultragenyx's (RARE) marketed drugs, which are approved for various indications, are driving the top line....
By Zacks Investment Research - 7 weeks ago

2 Best Biotech Stocks to Buy Right Now
Demand for medicines and vaccines has nowhere to go but up over the long run.
By The Motley Fool - 7 weeks ago

Sanofi's (SNY) Dupixent Gets Europe Nod for Prurigo Nodularis
The EC approves Sanofi (SNY) and its partner Regeneron's Dupixent for the treatment of adult...
By Zacks Investment Research - 7 weeks ago

Regeneron (REGN) Presents Positive Data on MM and FL Drugs
Regeneron (REGN) releases positive initial data on two candidates - linvoseltamab and odronextamab at ASH.
By Zacks Investment Research - 7 weeks ago
This fund beats the S&P 500 by using just 75 of its components. Here's how it works.
A combination of quality and lower prices has worked well through bull and bear markets...
By MarketWatch - 7 weeks ago

Will This Potential Approval Be a Winner for Sanofi's Shareholders?
Sanofi and Regeneron's Dupixent moved closer to regulatory approval to treat another skin disease in...
By The Motley Fool - 8 weeks ago
This fund beats the S&P 500 by using just 75 of its components. Here's how it works.
A combination of quality and lower prices has worked well through bull and bear markets...
By MarketWatch - 8 weeks ago